RESUMEN
Studied concentration of lactate and pyruvate in patiens with lung tuberculosis with disorders of tolerance to glucosis and glukemic disorders on an empty stomach and in patiens, wich had not such disorders. In patiens with preclinical disorders glicemia discovered increasing to concentrations of lactate and pyruvate in blood. This is indicative of more deep breaches of quality to oxidation the glucose in energetic aerobic reaction, in particular, in tricarboxylic acids cycle. Effect this is a deterioration energy status of the cells. Excess of the formation lactate and pyruvate on background of the effect anty-insulin hormone prevalence and relative insufficiency of the insulin realizes the independent contribution to development hyperglicemia disorders.
Asunto(s)
Metabolismo de los Hidratos de Carbono , Hiperglucemia/metabolismo , Ácido Láctico/sangre , Ácido Pirúvico/sangre , Tuberculosis Pulmonar/metabolismo , Glucemia/análisis , Estudios de Casos y Controles , Prueba de Tolerancia a la Glucosa , Humanos , Hiperglucemia/sangre , Insulina/sangre , Tuberculosis Pulmonar/sangreRESUMEN
The content of glycated hemoglobin, a biomarker of diabetes in patients with type 2 diabetes correlates with risk factors for cardiovascular disease: hypertension, BMI and ratio of total cholesterol to HDL cholesterol. Therefore, increase in glycosylated hemoglobin should be considered a predictor of cardiovascular disease in patients with type 2 diabetes.
Asunto(s)
Enfermedades Cardiovasculares/etiología , Colesterol/sangre , Diabetes Mellitus Tipo 2/complicaciones , Hemoglobina Glucada/análisis , Lipoproteínas HDL/sangre , Adulto , Anciano , Biomarcadores/sangre , Enfermedades Cardiovasculares/sangre , Diabetes Mellitus Tipo 2/sangre , Femenino , Humanos , Masculino , Persona de Mediana Edad , Factores de RiesgoRESUMEN
A total of 154 patients with type-I insulin-nondependent diabetes mellitus were examined together with 222 patients presenting with type-II insulin-nondependent diabetes mellitus. In glycemia of up to 6.66 mmol/l the level of blood plasma cholesterol was (5.40 +/- 0.02) mmol/l; with 7.77 mmol/l it came up to (6.33 +/- 0.02) mmol/l. Correlation has been shown to exist between fast glycemia and decline in the HDLP levels of cholesterol and rise in the atherogenicity factor. The content of MDA in plasma, LDLP + VLDLP, erythrocytes appeared to be related to the content of glycosylated hemoglobin. The author arrives at a conclusion that decompensation of DM is the most important factor of atherogenesis, attainment of a stable compensation is an essential condition of prevention of atherosclerosis further development in DM patients.
Asunto(s)
Arteriosclerosis/etiología , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Angiopatías Diabéticas/etiología , Arteriosclerosis/sangre , Glucemia/metabolismo , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 2/sangre , Angiopatías Diabéticas/sangre , Progresión de la Enfermedad , Ayuno/sangre , Femenino , Radicales Libres/sangre , Humanos , Peroxidación de Lípido , Lípidos/sangre , MasculinoRESUMEN
Diabetic patients have been shown to derive great benefit from treatment with laser therapy as evidenced by experience gained with its use over many years. Laser therapy promotes compensation, has an antiatherogenic, antioxidant, immunomodulating effects, improves microcirculation, myocardial contractility and performance capability.
Asunto(s)
Diabetes Mellitus Tipo 1/radioterapia , Diabetes Mellitus Tipo 2/radioterapia , Terapia por Láser , Puntos de Acupuntura , Enfermedad Crónica , Diabetes Mellitus Tipo 1/complicaciones , Diabetes Mellitus Tipo 1/inmunología , Diabetes Mellitus Tipo 1/fisiopatología , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/inmunología , Diabetes Mellitus Tipo 2/fisiopatología , Neuropatías Diabéticas/inmunología , Neuropatías Diabéticas/fisiopatología , Neuropatías Diabéticas/radioterapia , Equipos y Suministros , Cardiopatías/inmunología , Cardiopatías/fisiopatología , Cardiopatías/radioterapia , Humanos , Resultado del TratamientoRESUMEN
Carbonic fibrous enterosorbent "Vuglesorb" used as a part of complex anti-diabetic treatment contributes to normalization of metabolism, promotes liquidation of ketoacidosis and principal morbid manifestations. Alongside with this, glycaemia and fructosamine blood level come to the norm. Marked anti-atherogenic effect was also observed. The drug is recommended for the treatment of patients with diabetes mellitus.
